Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2115438 | Cancer Letters | 2007 | 10 Pages |
Abstract
Metastatic liver tumors are highly malignant and refractory to conventional therapies. TRAIL-resistant CT-26 cells underwent apoptosis in vitro in the presence of both recombinant TRAIL (rTRAIL) and a suboptimal dose of actinomycin D (ACD). Co-administration of soluble TRAIL (sTRAIL) gene and ACD suppressed the metastatic liver tumors of CT-26, significantly inducing apoptosis in the tumors, while such effects were not demonstrated in mice that received either the sTRAIL gene or ACD alone. The gene therapy of sTRAIL with a suboptimal dose of an anticancer drug is a new strategy for treatment of multiple liver metastasis.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Michiaki Ishii, Masaki Iwai, Yoshinori Harada, Tsunao Kishida, Hidetsugu Asada, Masaharu Shin-Ya, Yoshito Itoh, Jiro Imanishi, Takeshi Okanoue, Osam Mazda,